<DOC>
	<DOC>NCT00091793</DOC>
	<brief_summary>This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.</brief_summary>
	<brief_title>Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Eligibility Criteria Postmenopausal women with Osteopenia (lumbar spine bone mineral density Tscore between 1.0 and 2.5)</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>